2022
DOI: 10.1177/17588359221126154
|View full text |Cite
|
Sign up to set email alerts
|

Identification of an endogenous retroviral signature to predict anti-PD1 response in advanced clear cell renal cell carcinoma: an integrated analysis of three clinical trials

Abstract: Background: Endogenous retrovirus (ERV) elements are genomic footprints of ancestral retroviral infections within the human genome. Previous studies have demonstrated that dysregulated ERV transcription level is associated with immune cell infiltration in cancers, but the association between ERV expression and programmed cell death protein 1 (PD-1) blockade response is currently unraveled for solid cancers, such as advanced clear cell renal cell carcinoma (ccRCC). Methods: ERV mRNA profiles were obtained from … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 39 publications
(55 reference statements)
0
0
0
Order By: Relevance
“…A signature based on SHC1, IRF7, KDR, JAK3, and CXCL5 shows that in high-risk patients, there is a higher relative abundance of TFH cells, regulatory T cells, and M0 macrophages in tumors, as well as higher expression of PD1, CTLA-4, LAG3, and CD47, suggesting potential benefits from immune checkpoint inhibitor therapy [ 146 ]. Another study established an ERV signature based on nine ERV expression patterns, showing that patients in the low-risk group have better survival outcomes with nivolumab treatment [ 147 ]. A signature composed of PML, CDKN2B, COL1A2, CHRDL1, HPGD, CGN, and TGFBR3 indicates that patients in the high-risk group benefit more from immune therapy [ 148 ].…”
Section: Predictive and Resistance Factors For Pd1/pd-l1 Inhibition I...mentioning
confidence: 99%
“…A signature based on SHC1, IRF7, KDR, JAK3, and CXCL5 shows that in high-risk patients, there is a higher relative abundance of TFH cells, regulatory T cells, and M0 macrophages in tumors, as well as higher expression of PD1, CTLA-4, LAG3, and CD47, suggesting potential benefits from immune checkpoint inhibitor therapy [ 146 ]. Another study established an ERV signature based on nine ERV expression patterns, showing that patients in the low-risk group have better survival outcomes with nivolumab treatment [ 147 ]. A signature composed of PML, CDKN2B, COL1A2, CHRDL1, HPGD, CGN, and TGFBR3 indicates that patients in the high-risk group benefit more from immune therapy [ 148 ].…”
Section: Predictive and Resistance Factors For Pd1/pd-l1 Inhibition I...mentioning
confidence: 99%